Annovis Bio, Inc. (ANVS)

10.10 +0.25 (+2.58%) As of 11:48AM EDT. Market open.

Annovis Bio, Inc.

1055 Westlakes Drive
Suite 300
Berwyn, PA 19312
United States
610 727 3913
https://www.annovisbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 6

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Maria L. Maccecchini Ph.D.	Founder, CEO, President & Executive Director	965.6k	N/A	1951
Mr. Henry Hagopian III, M.B.A.	Chief Financial Officer	510.05k	N/A	1968
Dr. Cheng Fang Ph.D.	Senior Vice President of Research & Development	N/A	N/A	N/A
Ms. Eve M. Damiano M.S., RAC	Senior Vice President of Regulatory Operations	N/A	N/A	N/A
Ms. Melissa Gaines	Senior Vice President of Clinical Operations	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

Corporate governance

Annovis Bio, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.